forward-looking statements are identified by words such as “ believe , ” “ will , ” “ may , ” “ estimate , ” “ continue , ” “ anticipate , ” “ intend , ” “ should , ” “ plan , ” “ expect , ” “ predict , ” “ could , ” “ potentially ” or the negative of these terms or similar expressions . you should read these statements carefully because they discuss future expectations , contain projections of future results of operations or financial condition , or state other “ forward-looking ” information . these statements relate to our future plans , objectives , expectations , intentions and financial performance and the assumptions that underlie these statements . these forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements . factors that might cause such a difference include , but are not limited to , those discussed in this report in part i , item 1a — “ risk factors , ” and elsewhere in this report . forward-looking statements are based on our management 's beliefs and assumptions and on information currently available to our management . these statements , like all statements in this report , speak only as of their date , and we undertake no obligation to update or revise these statements in light of future developments . we caution investors that our business and financial performance are subject to substantial risks and uncertainties . overview we are a clinical-stage bio-pharmaceutical company focused on fighting cancer by discovering and developing novel small molecule oncology drugs that target tumor and immune cell metabolism . tumor metabolism and immuno-oncology have emerged as promising new fields for cancer drug discovery , and recent clinical successes with therapeutic agents in each field have demonstrated the potential to create fundamentally new therapies for cancer patients . with our unique oncometabolism approach , we have discovered two small molecule drug candidates that are currently in clinical development . these agents take advantage of the unique metabolic requirements of tumor cells and cancer-fighting immune cells . our lead product candidate , cb-839 , is an internally discovered , first-in-class oral inhibitor of glutaminase , a critical enzyme in tumor cells . our strategy is to develop cb-839 as combination therapy with approved agents , in order to improve the treatment of patients with cancer . we are currently evaluating cb‑839 in multiple phase 2 trials in patients with renal cell carcinoma , triple negative breast cancer , and other solid tumors . cb-839 is currently in a phase 1/2 trial in combination with nivolumab for the treatment of solid tumors . our product candidate , incb001158 , also known as cb-1158 , is a first-in-class oral inhibitor of arginase , an enzyme that depletes the amino acid arginine , a key metabolic nutrient for t‑cells , and it is being co-developed with incyte corporation , or incyte , for hematology and oncology indications . incb001158 is currently being tested in multiple phase 1/2 trials as a monotherapy and in combination with other anti-cancer agents . we are a fully integrated biopharmaceutical company with expertise in biology and chemistry , and our ongoing research efforts are focused on discovering additional product candidates against novel tumor metabolism and immunology targets . our lead product candidate , cb-839 , takes advantage of the pronounced dependency many cancers have on the nutrient glutamine for growth and survival . cb-839 inhibits glutaminase , an enzyme required by cancer cells to utilize glutamine effectively . in preclinical studies , cb-839 demonstrated broad antitumor activity in tumor cell lines , inhibited the growth of human tumors in animal models , and was well-tolerated in toxicity studies . cb-839 was also synergistic with several different classes of approved , standard of care cancer therapeutics . cb-839 may also have the potential to work in combination with immuno-oncology , or i-o therapeutics . glutamine , which is frequently depleted in the tumor microenvironment due to avid uptake by tumor cells , has been shown to be an important nutrient for t-cell proliferation . administration of cb-839 to tumor-bearing animals substantially enhances the anti-tumor activity of checkpoint inhibitors and thereby enables t-cells to proliferate . we believe cb-839 has the potential to be an important new therapeutic agent with a novel mechanism of action for the treatment of a broad range of cancers , and is the only selective glutaminase inhibitor currently in clinical trials . we currently retain all commercial rights to cb-839 and have been granted a u.s. patent , which includes composition of matter coverage for cb-839 through 2032. our product candidate incb001158 , is a potent and selective orally bioavailable inhibitor of the enzyme arginase , that was discovered at calithera and is being co-developed with incyte . arginase depletes arginine , a nutrient that is critical for the activation and proliferation of the body 's cancer-fighting immune cells , such as cytotoxic t-cells and natural killer ( nk ) -cells . during normal activation of the immune system , arginase , which is expressed by suppressive myeloid immune cells , plays an important role in halting t-cell proliferation . but in many tumors , including lung , gastrointestinal , bladder , renal cancer , squamous cell cancer of the head and neck , and acute myeloid leukemia , arginase-expressing myeloid cells accumulate and maintain an immunosuppressive 46 environment , bl ocking the ability of t-cells and nk-cells to kill cancer cells . story_separator_special_tag general and administrative general and administrative expenses increased $ 1.5 million , or 17 % , from $ 9.1 million for 2015 to $ 10.6 million for 2016. the increase was due to an increase of $ 1.2 million in personnel-related costs as a result of higher headcount , salary increases and stock-based compensation expense , $ 0.3 million due to a one-time severance charge related to a former employee , and an increase of $ 0.2 million in professional services costs primarily related to legal costs to support our patent portfolio , partially offset by a decrease of $ 0.2 million for a payment to a third party related to a terminated license arrangement . liquidity and capital resources as of december 31 , 2017 , we had cash , cash equivalents and investments totaling $ 186.2 million . our operations have been financed by net proceeds from the sale of shares of our capital stock and payments from the incyte collaboration agreement . 51 in august 2017 , we filed a shelf registration statement on form s-3 with the securities and exchange commission which permits the offering , issuance and sale by us of up to a maximum aggregate offering price of $ 250.0 million of our common stock , or the 2017 registration statement , replacing the shelf registration statement on form s-3 we filed with the securities and exchange commission in november 2015 , which permitted the offering , issuance and sale by us of up to a maximum aggregate offering price of $ 150.0 million of our common stock , or the 2015 registration statement . $ 50.0 million of the maximum aggregate offering price of $ 150.0 million was issued and sold pursuant to an atm for sales of our common stock under a sales agreement with cowen and company , llc , or cowen , our placement agent , under our 2015 registration statement , or the 2015 atm . as of december 31 , 2017 , $ 248.3 million of our common stock remained available for sale pursuant to the 2017 registration statement , of which up to $ 48.3 million may be issued and sold pursuant to an at-the-market offering program , or 2017 atm program , for sales of our common stock under a sales agreement with cowen , subject to cert ain conditions as specified in the sales agreement . during the year ended december 31 , 2017 , we sold an aggregate of : 7,854,500 shares of common stock pursuant to an underwriting agreement with leerink partners llc as representative of the several underwriters at a public offering price of $ 10.25 per share for gross proceeds of $ 80.5 million , resulting in net proceeds of $ 75.4 million after deducting underwriting fees and offering expenses under our 2015 registration statement . 4,351,114 shares of common stock pursuant to our 2015 atm and 2017 atm , at an average price of approximately $ 9.11 per share for gross proceeds of $ 39.6 million , resulting in net proceeds of $ 38.3 million after deducting underwriting fees and offering expenses ; and 1 , 720 ,430 shares of common stock pursuant to our stock purchase agreement with incyte , at a price of $ 4.65 per share for gross proceeds of $ 8.0 million , resulting in net proceeds of $ 7.9 million after deducting offering expenses under our 2015 registration statement . our primary uses of cash are to fund operating expenses , primarily research and development expenditures . cash used to fund operating expenses is impacted by the timing of when we pay these expenses , as reflected in the change in our outstanding accounts payable and accrued expenses . we believe that our existing cash , cash equivalents and investments as of december 31 , 2017 will be sufficient for us to meet our current operating plan for at least the twelve-month period following the filing of our 2017 form 10-k. however , our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties , and actual results could vary materially . in order to complete the process of obtaining regulatory approval for our product candidates and to build the sales , marketing and distribution infrastructure that we believe will be necessary to commercialize our product candidates , if approved , we will require substantial additional funding . we have based our projections of operating capital requirements on assumptions that may prove to be incorrect and we may use all of our available capital resources sooner than we expect . because of the numerous risks and uncertainties associated with research , development and commercialization of pharmaceutical products , we are unable to estimate the exact amount of our operating capital requirements . our future funding requirements will depend on many factors , including , but not limited to : the timing and costs of our planned clinical trials for our product candidates ; the timing and costs of our planned preclinical studies of our product candidates ; our success in establishing and scaling commercial manufacturing capabilities ; the number and characteristics of product candidates that we pursue ; the outcome , timing and costs of seeking regulatory approvals ; subject to receipt of regulatory approval , revenue received from commercial sales of our product candidates ; the terms and timing of any future collaborations , licensing , consulting or other arrangements that we may establish ; the amount and timing of any payments we may be required to make in connection with the licensing , filing , prosecution , maintenance , defense and enforcement of any patents or patent applications or other intellectual property rights ; and the extent to which we in-license or acquire other products and technologies . we plan to continue to fund our operations and capital funding needs through reimbursement of expenses under our

cash flows from operating activities cash provided by operating activities for the year ended december 31 , 2017 was $ 13.8 million . our net loss of $ 27.8 million was offset in part by non-cash charges of $ 5.5 million of stock-based compensation and $ 0.8 million for depreciation and amortization . the change in operating assets and liabilities was primarily related to a $ 31.0 million increase in deferred revenue due to our incyte collaboration agreement and a $ 5.3 million increase primarily due to the timing of payments for our clinical trial and manufacturing activities , partially offset by a $ 1.1 million increase in the receivables related to our collaboration agreements , primarily the incyte collaboration agreement . cash used in operating activities for the year ended december 31 , 2016 was $ 31.0 million , consisting of a net loss of $ 38.0 million , which was offset by non-cash charges $ 0.9 million for depreciation and amortization expense and $ 4.3 million for stock-based compensation . the change in our net operating assets and liabilities of $ 1.8 million was primarily due to the timing of payments for our clinical trial and manufacturing activities .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```cash flows from operating activities cash provided by operating activities for the year ended december 31 , 2017 was $ 13.8 million . our net loss of $ 27.8 million was offset in part by non-cash charges of $ 5.5 million of stock-based compensation and $ 0.8 million for depreciation and amortization . the change in operating assets and liabilities was primarily related to a $ 31.0 million increase in deferred revenue due to our incyte collaboration agreement and a $ 5.3 million increase primarily due to the timing of payments for our clinical trial and manufacturing activities , partially offset by a $ 1.1 million increase in the receivables related to our collaboration agreements , primarily the incyte collaboration agreement . cash used in operating activities for the year ended december 31 , 2016 was $ 31.0 million , consisting of a net loss of $ 38.0 million , which was offset by non-cash charges $ 0.9 million for depreciation and amortization expense and $ 4.3 million for stock-based compensation . the change in our net operating assets and liabilities of $ 1.8 million was primarily due to the timing of payments for our clinical trial and manufacturing activities .
```    
 Suspicious Activity Report : forward-looking statements are identified by words such as “ believe , ” “ will , ” “ may , ” “ estimate , ” “ continue , ” “ anticipate , ” “ intend , ” “ should , ” “ plan , ” “ expect , ” “ predict , ” “ could , ” “ potentially ” or the negative of these terms or similar expressions . you should read these statements carefully because they discuss future expectations , contain projections of future results of operations or financial condition , or state other “ forward-looking ” information . these statements relate to our future plans , objectives , expectations , intentions and financial performance and the assumptions that underlie these statements . these forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements . factors that might cause such a difference include , but are not limited to , those discussed in this report in part i , item 1a — “ risk factors , ” and elsewhere in this report . forward-looking statements are based on our management 's beliefs and assumptions and on information currently available to our management . these statements , like all statements in this report , speak only as of their date , and we undertake no obligation to update or revise these statements in light of future developments . we caution investors that our business and financial performance are subject to substantial risks and uncertainties . overview we are a clinical-stage bio-pharmaceutical company focused on fighting cancer by discovering and developing novel small molecule oncology drugs that target tumor and immune cell metabolism . tumor metabolism and immuno-oncology have emerged as promising new fields for cancer drug discovery , and recent clinical successes with therapeutic agents in each field have demonstrated the potential to create fundamentally new therapies for cancer patients . with our unique oncometabolism approach , we have discovered two small molecule drug candidates that are currently in clinical development . these agents take advantage of the unique metabolic requirements of tumor cells and cancer-fighting immune cells . our lead product candidate , cb-839 , is an internally discovered , first-in-class oral inhibitor of glutaminase , a critical enzyme in tumor cells . our strategy is to develop cb-839 as combination therapy with approved agents , in order to improve the treatment of patients with cancer . we are currently evaluating cb‑839 in multiple phase 2 trials in patients with renal cell carcinoma , triple negative breast cancer , and other solid tumors . cb-839 is currently in a phase 1/2 trial in combination with nivolumab for the treatment of solid tumors . our product candidate , incb001158 , also known as cb-1158 , is a first-in-class oral inhibitor of arginase , an enzyme that depletes the amino acid arginine , a key metabolic nutrient for t‑cells , and it is being co-developed with incyte corporation , or incyte , for hematology and oncology indications . incb001158 is currently being tested in multiple phase 1/2 trials as a monotherapy and in combination with other anti-cancer agents . we are a fully integrated biopharmaceutical company with expertise in biology and chemistry , and our ongoing research efforts are focused on discovering additional product candidates against novel tumor metabolism and immunology targets . our lead product candidate , cb-839 , takes advantage of the pronounced dependency many cancers have on the nutrient glutamine for growth and survival . cb-839 inhibits glutaminase , an enzyme required by cancer cells to utilize glutamine effectively . in preclinical studies , cb-839 demonstrated broad antitumor activity in tumor cell lines , inhibited the growth of human tumors in animal models , and was well-tolerated in toxicity studies . cb-839 was also synergistic with several different classes of approved , standard of care cancer therapeutics . cb-839 may also have the potential to work in combination with immuno-oncology , or i-o therapeutics . glutamine , which is frequently depleted in the tumor microenvironment due to avid uptake by tumor cells , has been shown to be an important nutrient for t-cell proliferation . administration of cb-839 to tumor-bearing animals substantially enhances the anti-tumor activity of checkpoint inhibitors and thereby enables t-cells to proliferate . we believe cb-839 has the potential to be an important new therapeutic agent with a novel mechanism of action for the treatment of a broad range of cancers , and is the only selective glutaminase inhibitor currently in clinical trials . we currently retain all commercial rights to cb-839 and have been granted a u.s. patent , which includes composition of matter coverage for cb-839 through 2032. our product candidate incb001158 , is a potent and selective orally bioavailable inhibitor of the enzyme arginase , that was discovered at calithera and is being co-developed with incyte . arginase depletes arginine , a nutrient that is critical for the activation and proliferation of the body 's cancer-fighting immune cells , such as cytotoxic t-cells and natural killer ( nk ) -cells . during normal activation of the immune system , arginase , which is expressed by suppressive myeloid immune cells , plays an important role in halting t-cell proliferation . but in many tumors , including lung , gastrointestinal , bladder , renal cancer , squamous cell cancer of the head and neck , and acute myeloid leukemia , arginase-expressing myeloid cells accumulate and maintain an immunosuppressive 46 environment , bl ocking the ability of t-cells and nk-cells to kill cancer cells . story_separator_special_tag general and administrative general and administrative expenses increased $ 1.5 million , or 17 % , from $ 9.1 million for 2015 to $ 10.6 million for 2016. the increase was due to an increase of $ 1.2 million in personnel-related costs as a result of higher headcount , salary increases and stock-based compensation expense , $ 0.3 million due to a one-time severance charge related to a former employee , and an increase of $ 0.2 million in professional services costs primarily related to legal costs to support our patent portfolio , partially offset by a decrease of $ 0.2 million for a payment to a third party related to a terminated license arrangement . liquidity and capital resources as of december 31 , 2017 , we had cash , cash equivalents and investments totaling $ 186.2 million . our operations have been financed by net proceeds from the sale of shares of our capital stock and payments from the incyte collaboration agreement . 51 in august 2017 , we filed a shelf registration statement on form s-3 with the securities and exchange commission which permits the offering , issuance and sale by us of up to a maximum aggregate offering price of $ 250.0 million of our common stock , or the 2017 registration statement , replacing the shelf registration statement on form s-3 we filed with the securities and exchange commission in november 2015 , which permitted the offering , issuance and sale by us of up to a maximum aggregate offering price of $ 150.0 million of our common stock , or the 2015 registration statement . $ 50.0 million of the maximum aggregate offering price of $ 150.0 million was issued and sold pursuant to an atm for sales of our common stock under a sales agreement with cowen and company , llc , or cowen , our placement agent , under our 2015 registration statement , or the 2015 atm . as of december 31 , 2017 , $ 248.3 million of our common stock remained available for sale pursuant to the 2017 registration statement , of which up to $ 48.3 million may be issued and sold pursuant to an at-the-market offering program , or 2017 atm program , for sales of our common stock under a sales agreement with cowen , subject to cert ain conditions as specified in the sales agreement . during the year ended december 31 , 2017 , we sold an aggregate of : 7,854,500 shares of common stock pursuant to an underwriting agreement with leerink partners llc as representative of the several underwriters at a public offering price of $ 10.25 per share for gross proceeds of $ 80.5 million , resulting in net proceeds of $ 75.4 million after deducting underwriting fees and offering expenses under our 2015 registration statement . 4,351,114 shares of common stock pursuant to our 2015 atm and 2017 atm , at an average price of approximately $ 9.11 per share for gross proceeds of $ 39.6 million , resulting in net proceeds of $ 38.3 million after deducting underwriting fees and offering expenses ; and 1 , 720 ,430 shares of common stock pursuant to our stock purchase agreement with incyte , at a price of $ 4.65 per share for gross proceeds of $ 8.0 million , resulting in net proceeds of $ 7.9 million after deducting offering expenses under our 2015 registration statement . our primary uses of cash are to fund operating expenses , primarily research and development expenditures . cash used to fund operating expenses is impacted by the timing of when we pay these expenses , as reflected in the change in our outstanding accounts payable and accrued expenses . we believe that our existing cash , cash equivalents and investments as of december 31 , 2017 will be sufficient for us to meet our current operating plan for at least the twelve-month period following the filing of our 2017 form 10-k. however , our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties , and actual results could vary materially . in order to complete the process of obtaining regulatory approval for our product candidates and to build the sales , marketing and distribution infrastructure that we believe will be necessary to commercialize our product candidates , if approved , we will require substantial additional funding . we have based our projections of operating capital requirements on assumptions that may prove to be incorrect and we may use all of our available capital resources sooner than we expect . because of the numerous risks and uncertainties associated with research , development and commercialization of pharmaceutical products , we are unable to estimate the exact amount of our operating capital requirements . our future funding requirements will depend on many factors , including , but not limited to : the timing and costs of our planned clinical trials for our product candidates ; the timing and costs of our planned preclinical studies of our product candidates ; our success in establishing and scaling commercial manufacturing capabilities ; the number and characteristics of product candidates that we pursue ; the outcome , timing and costs of seeking regulatory approvals ; subject to receipt of regulatory approval , revenue received from commercial sales of our product candidates ; the terms and timing of any future collaborations , licensing , consulting or other arrangements that we may establish ; the amount and timing of any payments we may be required to make in connection with the licensing , filing , prosecution , maintenance , defense and enforcement of any patents or patent applications or other intellectual property rights ; and the extent to which we in-license or acquire other products and technologies . we plan to continue to fund our operations and capital funding needs through reimbursement of expenses under our

